- Apricus' (APRI) shares gain 8% after the company signs an exclusive licensing agreement with Italy's Recordati (RCDTF) to market Apricus' Vitaros cream for erectile dysfunction in Spain, Russia, Turkey, Ireland and other European countries, and in some African markets.
- Apricus will receive $3.8M up front, as much as $47M in sales milestone payments and royalties. (PR)
Apricus signs Vitaros licensing deal, shares gain
Feb 10 2014, 09:55 ET